For more insights on the market share of various regions - Download a Sample Report
Active Pharmaceutical Ingredients (API) Market: Evolving API manufacturing scenario in developing countries to drive growth
- The key factor driving the active pharmaceutical ingredients (API) market growth is the evolving API manufacturing scenario in developing countries. Considering the presence of developed infrastructure and growing economic development, India and China have started producing high-quality APIs and drug intermediates for regulated markets.
- Generic drug manufacturers are keen to work directly with Indian and Chinese API manufacturers as the strategic outsourcing of APIs is necessary for obtaining high-profit margins, while the transfer of intellectual property for preparing APIs is less of a concern than the main monograph for preparing the finished drug products.
- On average, the manufacturing cost of APIs for generic oral solids, such as tablets and capsules, accounts for approximately 40%-50% of the production cost. In a highly competitive market, where the ability to offer a low price is vital, generic drug manufacturers seek competitive advantages by outsourcing bulk drug manufacturing activities to reliable API manufacturers in developing countries, who can deliver the APIs at a low cost. This is expected to drive the growth of the market during the forecast period.
To know more about other drivers along with the market challenges - Request a Sample Research Report
Active Pharmaceutical Ingredients (API) Market: Segmentation Analysis
The market research report segments the active pharmaceutical ingredients (API) market by Geographic (APAC, North America, Europe, and ROW) and Manufacturing type (captive APIs and contract APIs)
Revenue Generating Segment: The active pharmaceutical ingredients (API) market share growth by the captive APIs will be significant for revenue generation. The increased adoption of healthcare services has benefited the global active pharmaceutical ingredients (API) market significantly. There is a huge focus on increasing the accessibility to affordable healthcare services, and this has led to increased demand for access to low-cost medicines, in turn inducing the demand for low-cost APIs for manufacturing the finished drugs.
To gain further insights into the market contribution of various segments - Download a sample report
Get ready to achieve excellent business outcomes from this exclusive Active Pharmaceutical Ingredients (API) Market report by Technavio. The report will include highlights of the overall market which includes frequently asked questions such as -
- What are historical revenue figures and estimated revenue figures as well as CAGR during the forecast timeframe?
- What is the current trend taking place in the market space?|
- Which are business tactics that will influence competitive scenarios along with defining the growth potential of the market?
- What are market drivers, restraints, and challenges impacting demand & growth of the market?
- Which regions & segments will garner massive revenue and emerge as market leaders in upcoming years?
The competitive scenario provided in the Active Pharmaceutical Ingredients (API) Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Don't wait, Make a strategic approach & boost your business goals with our Active Pharmaceutical Ingredients (API) Market Forecast Report - Buy Now!
Related Reports:
- The pharmaceutical glycerine market share is expected to increase by USD 56.35 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.92%. Download a sample now!
- The marine pharmaceuticals market size is predicted to surge by USD 1.56 billion from 2021 to 2026 at a CAGR of 7.73%. Download a sample now!
Active Pharmaceutical Ingredients (API) Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.1% |
Market growth 2021-2025 |
USD 64.53 billion |
Market structure |
Fragmented |
YoY growth (%) |
5.80 |
Performing market contribution |
APAC at 66% |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline Plc, Koninklijke DSM NV, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Content:
1 Executive Summary
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 01: Parent market
- 2.2 Market characteristics
- Exhibit 02: Market characteristics
- 2.3 Value chain analysis
- Exhibit 03: Value chain analysis - Pharmaceuticals market
3 Market Sizing
- 3.1 Market definition
- Exhibit 04: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 05: Market segments
- 3.4 Market outlook: Forecast for 2020 - 2025
- Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ billion)
- Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 08: Five forces analysis 2020 & 2025
- 4.2 Bargaining power of buyers
- Exhibit 09: Bargaining power of buyers
- 4.3 Bargaining power of suppliers
- Exhibit 10: Bargaining power of suppliers
- 4.4 Threat of new entrants
- Exhibit 11: Threat of new entrants
- 4.5 Threat of substitutes
- Exhibit 12: Threat of substitutes
- 4.6 Threat of rivalry
- Exhibit 13: Threat of rivalry
- 4.7 Market condition
- Exhibit 14: Market condition - Five forces 2020
5 Market Segmentation by Manufacturing Type
- 5.1 Market segments
- Exhibit 15: Manufacturing type - Market share 2020-2025 (%)
- 5.2 Comparison by manufacturing type
- Exhibit 16: Comparison by manufacturing type
- 5.3 Captive APIs - Market size and forecast 2020-2025
- Exhibit 17: Captive APIs - Market size and forecast 2020-2025 ($ billion)
- Exhibit 18: Captive APIs - Year-over-year growth 2020-2025 (%)
- 5.4 Contract APIs - Market size and forecast 2020-2025
- Exhibit 19: Contract APIs - Market size and forecast 2020-2025 ($ billion)
- Exhibit 20: Contract APIs - Year-over-year growth 2020-2025 (%)
- 5.5 Market opportunity by manufacturing type
- Exhibit 21: Market opportunity by manufacturing type
6 Customer landscape
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 23: Market share by geography 2020-2025 (%)
- 7.2 Geographic comparison
- Exhibit 24: Geographic comparison
- 7.3 APAC - Market size and forecast 2020-2025
- Exhibit 25: APAC - Market size and forecast 2020-2025 ($ billion)
- Exhibit 26: APAC - Year-over-year growth 2020-2025 (%)
- 7.4 North America - Market size and forecast 2020-2025
- Exhibit 27: North America - Market size and forecast 2020-2025 ($ billion)
- Exhibit 28: North America - Year-over-year growth 2020-2025 (%)
- 7.5 Europe - Market size and forecast 2020-2025
- Exhibit 29: Europe - Market size and forecast 2020-2025 ($ billion)
- Exhibit 30: Europe - Year-over-year growth 2020-2025 (%)
- 7.6 ROW - Market size and forecast 2020-2025
- Exhibit 31: ROW - Market size and forecast 2020-2025 ($ billion)
- Exhibit 32: ROW - Year-over-year growth 2020-2025 (%)
- 7.7 Key leading countries
- Exhibit 33: Key leading countries
- 7.8 Market opportunity by geography
8 Drivers, Challenges, and Trends
- 8.2 Market challenges
- Exhibit 36: Impact of drivers and challenges
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 37: Vendor landscape
- 9.3 Landscape disruption
- Exhibit 38: Landscape disruption
- Exhibit 39: Industry risks
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 40: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 41: Market positioning of vendors
- 10.3 Amneal Pharmaceuticals Inc.
- Exhibit 42: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 43: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 44: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 45: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 46: Amneal Pharmaceuticals Inc. - Segment focus
- 10.4 Cadila Healthcare Ltd.
- 10.5 Dr. Reddy's Laboratories Ltd.
- Exhibit 52: Dr. Reddy's Laboratories Ltd. - Overview
- Exhibit 53: Dr. Reddy's Laboratories Ltd. - Business segments
- Exhibit 54: Dr. Reddy's Laboratories Ltd. - Key news
- Exhibit 55: Dr. Reddy's Laboratories Ltd. - Key offerings
- Exhibit 56: Dr. Reddy's Laboratories Ltd. - Segment focus
- 10.6 GlaxoSmithKline Plc
- Exhibit 57: GlaxoSmithKline Plc - Overview
- Exhibit 58: GlaxoSmithKline Plc - Business segments
- Exhibit 59: GlaxoSmithKline Plc - Key news
- Exhibit 60: GlaxoSmithKline Plc - Key offerings
- Exhibit 61: GlaxoSmithKline Plc - Segment focus
- 10.7 Koninklijke DSM NV
- Exhibit 62: Koninklijke DSM NV - Overview
- Exhibit 63: Koninklijke DSM NV - Business segments
- Exhibit 64: Koninklijke DSM NV - Key news
- Exhibit 65: Koninklijke DSM NV - Key offerings
- Exhibit 66: Koninklijke DSM NV - Segment focus
- 10.8 Mylan NV
- Exhibit 67: Mylan NV - Overview
- Exhibit 68: Mylan NV - Business segments
- Exhibit 69: Mylan NV - Key news
- Exhibit 70: Mylan NV - Key offerings
- Exhibit 71: Mylan NV - Segment focus
- 10.9 Novartis AG
- Exhibit 72: Novartis AG - Overview
- Exhibit 73: Novartis AG - Business segments
- Exhibit 74: Novartis AG - Key news
- Exhibit 75: Novartis AG - Key offerings
- Exhibit 76: Novartis AG - Segment focus
- 10.10 Pfizer Inc.
- Exhibit 77: Pfizer Inc. - Overview
- Exhibit 78: Pfizer Inc. - Business segments
- Exhibit 79: Pfizer Inc. - Key news
- Exhibit 80: Pfizer Inc. - Key offerings
- Exhibit 81: Pfizer Inc. - Segment focus
- 10.11 Sun Pharmaceutical Industries Ltd.
- Exhibit 82: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 83: Sun Pharmaceutical Industries Ltd. - Business segments
- Exhibit 84: Sun Pharmaceutical Industries Ltd- Key news
- Exhibit 85: Sun Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 86: Sun Pharmaceutical Industries Ltd. - Segment focus
- 10.12 Teva Pharmaceutical Industries Ltd.
- Exhibit 87: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 88: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 89: Teva Pharmaceutical Industries Ltd- Key news
- Exhibit 90: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 91: Teva Pharmaceutical Industries Ltd. - Segment focus
11 Appendix
- 11.2 Currency conversion rates for US$
- Exhibit 92: Currency conversion rates for US$
- 11.3 Research methodology
- Exhibit 93: Research Methodology
- Exhibit 94: Validation techniques employed for market sizing
- Exhibit 95: Information sources
- 11.4 List of abbreviations
- Exhibit 96: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article